Valar Labs

Valar Labs is a precision oncology company developing AI-powered diagnostics to help reduce uncertainty in cancer treatment decisions. Its models analyze pathology slides and tumor characteristics to provide physicians and patients with evidence-based insights into the likelihood that a therapy will work. The company’s reports are designed to make complex findings clear and actionable, supporting more informed choices about treatment.

Valar Labs offers its Vesta diagnostic platform, including Vesta Bladder and Vesta Prostate, and identifies Vitara among its offerings. The company says Vesta is the only bladder cancer diagnostic that predicts response to BCG treatment using routine histology. Its broader approach focuses on uncovering insights into the tumor microenvironment and its effects on treatment response.

Valar Labs also partners with pharmaceutical companies to advance research and development. Its work includes discovering biomarkers associated with therapy response, deploying diagnostics for those biomarkers, and automating molecular biomarker screening to support trial enrollment and reduce costs.